Biopharmaceutical Excipients Market Size & Growth Report

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Biopharmaceutical Excipients Market Size Analysis

Global Biopharmaceutical Excipients Market Introduction
By Excipient
1. Introduction
  1. Excipient By Value
2. Bulking Agents
  1. By Value
3. Solubilizers and Surfactants
  1. By Value
4. Buffering and Tonicity Agents
  1. By Value
5. Others
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharma and Biotech Companies
  1. By Value
3. CMOS and CDMOS
  1. By Value
4. Academic and Research Institutes
  1. By Value

North America Market Analysis

Introduction
By Excipient
1. Introduction
  1. Excipient By Value
2. Bulking Agents
  1. By Value
3. Solubilizers and Surfactants
  1. By Value
4. Buffering and Tonicity Agents
  1. By Value
5. Others
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharma and Biotech Companies
  1. By Value
3. CMOS and CDMOS
  1. By Value
4. Academic and Research Institutes
  1. By Value
U.S.
1. By Excipient
  1. Introduction
    1. Excipient By Value
  2. Bulking Agents
    1. By Value
  3. Solubilizers and Surfactants
    1. By Value
  4. Buffering and Tonicity Agents
    1. By Value
  5. Others
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharma and Biotech Companies
    1. By Value
  3. CMOS and CDMOS
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Canada

Europe Market Analysis

Introduction
By Excipient
1. Introduction
  1. Excipient By Value
2. Bulking Agents
  1. By Value
3. Solubilizers and Surfactants
  1. By Value
4. Buffering and Tonicity Agents
  1. By Value
5. Others
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharma and Biotech Companies
  1. By Value
3. CMOS and CDMOS
  1. By Value
4. Academic and Research Institutes
  1. By Value
U.K.
1. By Excipient
  1. Introduction
    1. Excipient By Value
  2. Bulking Agents
    1. By Value
  3. Solubilizers and Surfactants
    1. By Value
  4. Buffering and Tonicity Agents
    1. By Value
  5. Others
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharma and Biotech Companies
    1. By Value
  3. CMOS and CDMOS
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Excipient
1. Introduction
  1. Excipient By Value
2. Bulking Agents
  1. By Value
3. Solubilizers and Surfactants
  1. By Value
4. Buffering and Tonicity Agents
  1. By Value
5. Others
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharma and Biotech Companies
  1. By Value
3. CMOS and CDMOS
  1. By Value
4. Academic and Research Institutes
  1. By Value
China
1. By Excipient
  1. Introduction
    1. Excipient By Value
  2. Bulking Agents
    1. By Value
  3. Solubilizers and Surfactants
    1. By Value
  4. Buffering and Tonicity Agents
    1. By Value
  5. Others
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharma and Biotech Companies
    1. By Value
  3. CMOS and CDMOS
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Excipient
1. Introduction
  1. Excipient By Value
2. Bulking Agents
  1. By Value
3. Solubilizers and Surfactants
  1. By Value
4. Buffering and Tonicity Agents
  1. By Value
5. Others
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharma and Biotech Companies
  1. By Value
3. CMOS and CDMOS
  1. By Value
4. Academic and Research Institutes
  1. By Value
UAE
1. By Excipient
  1. Introduction
    1. Excipient By Value
  2. Bulking Agents
    1. By Value
  3. Solubilizers and Surfactants
    1. By Value
  4. Buffering and Tonicity Agents
    1. By Value
  5. Others
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharma and Biotech Companies
    1. By Value
  3. CMOS and CDMOS
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Excipient
1. Introduction
  1. Excipient By Value
2. Bulking Agents
  1. By Value
3. Solubilizers and Surfactants
  1. By Value
4. Buffering and Tonicity Agents
  1. By Value
5. Others
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharma and Biotech Companies
  1. By Value
3. CMOS and CDMOS
  1. By Value
4. Academic and Research Institutes
  1. By Value
Brazil
1. By Excipient
  1. Introduction
    1. Excipient By Value
  2. Bulking Agents
    1. By Value
  3. Solubilizers and Surfactants
    1. By Value
  4. Buffering and Tonicity Agents
    1. By Value
  5. Others
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharma and Biotech Companies
    1. By Value
  3. CMOS and CDMOS
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Biopharmaceutical Excipients Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Merck KGAA
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
BASF SE
Avantor
Evonik Industries
Roquette Freres
Aceto
Angus Chemical
Apothecon
Ashland Global
BioSpectra
BOC Sciences
C.G. Group
Clariant
Colorcon
DFE Pharma
DOW
Eastman Chemical
IMCD N.V.
Innophos
Invitria

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment